India's medical devices market is one of the fastest growing in the world, driven by factors such as its increasing population, rising middle class, and governmental support.

Nevertheless, the market is characterised by intricate regulations, posing distinct challenges for stakeholders. When coupled with cost constraints and insufficient investment in research and development, the sector experiences adverse effects. By implementing a well-defined regulatory roadmap, placing a stronger emphasis on Production-Linked Incentive (PLI) schemes, and leveraging the benefits of the Make in India programme, the industry is poised for an upward trajectory.

Structuring capital for growth without dilution

Structuring capital for growth without dilution

Know more
1.
The challenge
The client required time-sensitive funding to support new product launches and manufacturing expansion while reducing debt. At the same time, promoters aimed to minimise dilution and retain control amid complex investor expectations.
2.
How we helped
We acted as an advisor and structured a hybrid funding solution using optionally convertible debentures. This approach enabled debt reduction, aligned investor interests, and limited promoter dilution while supporting growth objectives.
3.
The results
The transaction enabled timely capital infusion, repayment of high-cost debt, and preservation of promoter control. The client emerged with a stronger balance sheet and a resilient capital structure to support long-term growth.

    Our resources

    Complying with Uniform UCPMP 2024

    We help pharmaceutical and medical device companies comply with the Uniform Code for Pharmaceutical Marketing Practice.